enGene (NASDAQ:ENGN) Sees Large Volume Increase

Shares of enGene Holdings Inc. (NASDAQ:ENGN) saw strong trading volume on Friday . 96,435 shares traded hands during mid-day trading, an increase of 121% from the previous session’s volume of 43,541 shares.The stock last traded at $15.00 and had previously closed at $14.72.

Wall Street Analysts Forecast Growth

ENGN has been the subject of a number of recent research reports. Guggenheim began coverage on enGene in a research note on Monday, April 15th. They issued a “buy” rating and a $34.00 target price for the company. Wells Fargo & Company assumed coverage on shares of enGene in a report on Monday. They set an “overweight” rating and a $30.00 price objective for the company. Leerink Partnrs reiterated an “outperform” rating on shares of enGene in a research note on Tuesday, February 20th. UBS Group initiated coverage on enGene in a research report on Thursday, March 28th. They set a “buy” rating and a $37.00 target price for the company. Finally, Morgan Stanley initiated coverage on enGene in a research note on Friday, March 8th. They set an “overweight” rating and a $40.00 price objective for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $34.40.

enGene Price Performance

The firm has a fifty day moving average of $16.21.

Insider Buying and Selling at enGene

In other news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of enGene stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $15.00, for a total transaction of $717,810.00. Following the transaction, the insider now directly owns 3,036,153 shares of the company’s stock, valued at $45,542,295. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Institutional Investors Weigh In On enGene

Several large investors have recently made changes to their positions in ENGN. Vivo Capital LLC bought a new position in enGene during the 4th quarter worth about $6,264,000. Omega Fund Management LLC bought a new position in shares of enGene during the fourth quarter worth about $10,441,000. BVF Inc. IL bought a new stake in enGene in the 4th quarter valued at approximately $20,777,000. Finally, Fcpm Iii Services B.V. bought a new position in shares of enGene during the 4th quarter worth approximately $80,097,000. Institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.